Trials / Completed
CompletedNCT00351611
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lyrica (pregabalin) | 150 mg twice a day, oral administration |
| DRUG | placebo | Twice a day, oral administration |
Timeline
- Start date
- 2006-07-26
- Primary completion
- 2020-02-04
- Completion
- 2020-02-04
- First posted
- 2006-07-13
- Last updated
- 2021-04-13
- Results posted
- 2021-02-21
Locations
150 sites across 9 countries: United States, Bulgaria, Czechia, Hungary, India, Mexico, Poland, South Korea, Thailand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00351611. Inclusion in this directory is not an endorsement.